Hariharan, Vivek https://orcid.org/0009-0000-7001-0077
White, Jennifer A.
Dragoni, Filippo https://orcid.org/0000-0002-8148-9914
Fray, Emily J.
Pathoulas, Nicholas https://orcid.org/0000-0002-6071-0798
Moskovljevic, Milica https://orcid.org/0000-0003-0436-6854
Zhang, Hao
Singhal, Anushka
Lai, Jun
Beg, Subul A.
Scully, Eileen P. https://orcid.org/0000-0002-6687-6051
Gilliams, Elizabeth A.
Block, David S. https://orcid.org/0000-0003-4431-1233
Keruly, Jeanne
Moore, Richard D.
Siliciano, Janet D. https://orcid.org/0000-0001-6712-3775
Simonetti, Francesco R. https://orcid.org/0000-0002-4165-660X
Siliciano, Robert F. https://orcid.org/0000-0002-1764-1993
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (P01AI169615)
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (U01DA036935)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (DP5OD031834)
Johns Hopkins | School of Medicine, Johns Hopkins University (P30AI094189)
Article History
Received: 11 April 2025
Accepted: 27 August 2025
First Online: 3 October 2025
Competing interests
: R.F.S. is an inventor on a patent application for the intact proviral DNA assay (IPDA) (patent no. PCT/US16/28822) filed by Johns Hopkins University and licensed by AccelevirDx. F.R.S. received payments from Gilead Sciences for participating at scientific meetings. The other authors declare no competing interests.